BREAKWATER: Encorafenib, Cetuximab, and Chemotherapy for Mutant Metastatic Colorectal Cancer

Scott Kopetz, MD, PhD, of MD Anderson Cancer Center, discusses the phase 3 BREAKWATER study on the use of first-line encorafenib plus cetuximab with or without chemotherapy versus standard-of-care chemotherapy alone for BRAF V600E-mutant metastatic colorectal cancer.

Dr. Kopetz elaborates on the key efficacy and safety findings from the study, including how they compare to current standard treatment options for BRAF V600E-mutant mCRC, and what lies ahead for the future of BREAKWATER.